Also, combination therapies targeting PD-1/PD-L1 and CTLA-4 are very effective in patients with malignant melanoma (42, 43), microsatellite instability high colorectal cancer, and are being investigated in many ongoing clinical trials in patients with HCC (44). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.